ArticleJournal of cellular and molecular medicine2026
The Correlation of Enhanced Osteogenic Capability in Titanium Alloy Implants Through Modulation of the Runx2/BSP Pathway.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the mechanical properties, biocompatibility and osteogenic potential of titanium alloy implants (Ti6Al4V group) compared to conventional alloy implants (Ti4Al2V group). The mechanical performance tests, including ultimate tensile strength, elongation at break, yield strength and ultimate compressive strength, demonstrated superior results for the titanium alloy implants. In vitro cell experiments, comprising CCK-8 assay and ALP (alkaline phosphatase) staining, revealed significantly higher cell viability and osteogenic activity in the Ti6Al4V group. Additionally, in vivo animal experiments, including HE staining, flow cytometry, immunofluorescence assay. Ti-6Al-4V implants exhibited superior mechanical properties compared with conventional alloy implants, with a higher ultimate tensile strength (1200 ± 50 vs. 950 ± 45 MPa), greater elongation at break (15.2% ± 2.1% vs. 9.8% ± 1.7%), higher compressive yield strength (850 ± 40 vs. 720 ± 35 MPa) and higher ultimate compressive strength (1300 ± 60 vs. 1100 ± 50 MPa) (all p < 0.05). The elastic modulus of Ti-6Al-4V (10.8 ± 0.15 GPa) was lower than that of the conventional alloy (16.2 ± 0.18 GPa), closer to cancellous bone (~4 GPa), suggesting reduced stress shielding. In vitro, Ti-6Al-4V implants supported significantly higher MC3T3-E1 proliferation at 48 h (p < 0.01) and enhanced osteogenic differentiation, with ALP staining intensity of 450 ± 35 vs. 320 ± 28 and a higher percentage of ALP-positive cells (85% ± 4% vs. 60% ± 5%) compared with controls (both p < 0.05). In vivo, H&E staining showed more abundant and better-organised bone trabeculae around Ti-6Al-4V implants, while flow cytometry revealed reduced apoptosis in peri-implant tissues (p < 0.05). At the molecular level, Ti-6Al-4V implants significantly upregulated osteogenic markers: Runx2 protein expression was increased by 33% and BSP by 42% relative to the control alloy, accompanied by higher levels of osteocalcin (OCN) and collagen type I alpha 1 (COL1A1) (all p < 0.05). Ti4Al2V groupTi4Al2V group. These findings suggest that titanium alloy implants exhibit better biocompatibility and osteogenic capacity than conventional alloy implants, providing a strong foundation for their potential application in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.